<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Oral Maxillofac Res</journal-id><journal-id journal-id-type="iso-abbrev">J Oral Maxillofac Res</journal-id><journal-id journal-id-type="publisher-id">JORM</journal-id><journal-title-group><journal-title>Journal of Oral &#x00026; Maxillofacial Research</journal-title></journal-title-group><issn pub-type="epub">2029-283X</issn><publisher><publisher-name>Stilus Optimus</publisher-name><publisher-loc>Kaunas, Lithuania</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24422000</article-id><article-id pub-id-type="pmc">3886080</article-id><article-id pub-id-type="publisher-id">v2n4e3ht</article-id><article-id pub-id-type="doi">10.5037/jomr.2011.2403</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Preventive Effect of Rebamipide Gargle on Chemoradiotherpy-Induced Oral Mucositis in Patients with Oral Cancer: a Pilot Study</article-title></title-group><contrib-group><contrib id="contrib1" contrib-type="author" corresp="yes"><name><surname>Yasuda</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="contrib2" contrib-type="author"><name><surname>Chiba</surname><given-names>Hiroshige</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="contrib3" contrib-type="author"><name><surname>Satomi</surname><given-names>Takafumi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="contrib4" contrib-type="author"><name><surname>Matsuo</surname><given-names>Akira</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="contrib5" contrib-type="author"><name><surname>Kaneko</surname><given-names>Tadayoshi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="contrib6" contrib-type="author"><name><surname>Chikazu</surname><given-names>Daichi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="contrib7" contrib-type="author"><name><surname>Miyamatsu</surname><given-names>Hironobu</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1" rid="aff1"><sup>1</sup><institution>Department of Oral and Maxillofacial Surgery, Tokyo Medical
University</institution><addr-line>Tokyo</addr-line><country>Japan.</country></aff><aff id="aff2" rid="aff2"><sup>2</sup><institution>Department of Pharmacy, Tokyo Medical University Hospital</institution><addr-line>Tokyo</addr-line><country>Japan.</country></aff><author-notes><corresp>Takashi Yasuda,
<institution>Department of Oral and Maxillofacial Surgery, Tokyo Medical
University</institution><addr-line>6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo</addr-line><country>Japan</country><phone>+81-3-3342-6111</phone>
Fax: +81-3-3342-1723<email>t-yasu@tokyo-med.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><season>Oct-Dec</season><year>2011</year></pub-date><pub-date pub-type="epub"><day>1</day><month>1</month><year>2012</year></pub-date><volume>2</volume><issue>4</issue><elocation-id>e3</elocation-id><history><date date-type="received"><day>9</day><month>8</month><year>2011</year></date><date date-type="accepted"><day>5</day><month>11</month><year>2011</year></date></history><permissions><copyright-statement> Copyright &#x000a9; Yasuda T, Chiba H, Satomi T, Matsuo A, Kaneko
T, Chikazu D, Miyamatsu H. Published in the JOURNAL OF ORAL &#x00026;
MAXILLOFACIAL RESEARCH (http://www.ejomr.org), 1 January 2012.</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article, first published in the JOURNAL OF
ORAL &#x00026; MAXILLOFACIAL RESEARCH, distributed under the terms of the
Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Unported
License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and
reproduction in any medium, provided the original work and is properly
cited. The copyright, license information and link to the original
publication on <ext-link ext-link-type="uri" xlink:href="http://www.ejomr.org">http://www.ejomr.org</ext-link> must be included.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="http://www.ejomr.org/JOMR/archives/2011/4/e3/v2n4e3ht.htm"/><abstract><title>ABSTRACT</title><sec sec-type="objectives"><title>Objectives</title><p>To assess the efficacy and safety of rebamipide in preventing
chemoradiotherapy-induced oral mucositis in patients with oral cancer.</p></sec><sec sec-type="material and methods"><title>Material and Methods</title><p>Patients with oral cancer treated with chemoradiotherapy (daily radiotherapy
plus docetaxel hydrate once a week) were enrolled for this study. They were
assigned in a double-blind fashion to receive either rebamipide gargle or
placebo on the days of chemoradiotherapy. Oral mucositis was assessed using
the WHO grading system. The primary endpoint of this study was the incidence
of grade 3 - 4 mucositis after exposure to 40 Gy radiation (4 weeks). The
secondary endpoint was the effect of rebamipide gargle on tumour response to
chemoradiotherapy.</p></sec><sec sec-type="results"><title>Results</title><p>Twenty-four patients were randomly assigned to receive rebamipide gargle (n =
12) or placebo-gargle (n = 12) during chemoradiotherapy. The number of
patients with severe mucositis (WHO &#x02265; 3) was higher in the placebo group
than in the rebamipide group (83.3% vs. 33.3%, P = 0.036). In addition, no
effect of rebamipide gargle on tumour response to chemoradiotherapy was
recognized compared with the placebo group.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>For patients with oral cancer undergoing chemoradiotherapy, rebamipide gargle
may contribute to decrease the severity of oral mucositis.</p></sec></abstract><kwd-group><kwd>oral mucositis</kwd><kwd>chemotherapy</kwd><kwd>radiotherapy</kwd><kwd>rebamipide</kwd><kwd>oral cancer.</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>Cancer chemotherapy and radiotherapy have various significant adverse effects,
including oral mucositis, which is a painful condition and risk factor for infection
that can lead to impaired nutritional status and inadequate hydration, significantly
impairing the patients' quality of life. Furthermore, in some patients, it becomes a
dose-limiting toxicity, slowing or preventing continuation of cancer treatment
[<xref ref-type="bibr" rid="B1">1</xref>].</p><p>Oral mucositis is frequently observed in patients with cancer receiving high-dose
head and neck radiotherapy (85 - 100%), stem cell transplantation (75 - 100%), or
standard-dose chemotherapy for solid tumours (5 - 40%). Moreover, combined use of
chemotherapy and radiotherapy (chemoradiotherapy) for patients with head and neck
cancer may increase the incidence and severity of oral mucositis [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>Although the clinical features of oral mucositis are mainly the result of oral
epithelial injury, it is believed that oral mucositis is due to various causes,
including induction of direct epithelial cell injury and DNA strand breaks by
anti-neoplastic drugs or radiation, extensive cell injury resulting from the
generation of reactive oxygen species (free radicals) and cytotoxic cytokines (IL-8,
IL-1&#x003b2;, and TNF-&#x003b1;), infection, myelosuppression, and xerostomia [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. The
pathogenetic sequence of oral mucositis has been proposed by Sonis et al. [<xref ref-type="bibr" rid="B6">6</xref>] to include the following five steps: 1) an
initiation stage, 2) up-regulation and generation of messenger signals, 3) signaling
and amplification, 4) ulceration, and 5) a healing stage. </p><p>Rebamipide (Mucosta<sup>&#x000ae;</sup>, Tokyo, Japan) is a drug developed in Japan for the treatment of
gastritis and gastric ulcer. The mechanisms involved in the anti-ulcer and
cytoprotective effects of rebamipide have been reported to include induction of
prostaglandin E2 synthesis via COX-2 expression [<xref ref-type="bibr" rid="B7">7</xref>], up-regulation of growth factors and their receptors such as EGF
[<xref ref-type="bibr" rid="B8">8</xref>] and HGF [<xref ref-type="bibr" rid="B9">9</xref>], induction of mucus secretion [<xref ref-type="bibr" rid="B10">10</xref>], anti-free-radical effects [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>], and inhibition of the
production of inflammatory cytokines such as IL-1, IL-8, and TNF-&#x003b1; [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. </p><p>The mechanisms of onset of oral mucositis associated with chemoradiotherapy, which
include production of free radicals, increase of inflammatory cytokines, and
alteration of intracellular signal transduction, suggest that rebamipide should be
useful for its treatment and prevention. </p><p>Thus, we designed a randomised, double-blind, placebo-controlled trial of rebamipide
gargle solution in patients with head and neck cancer. The primary objective of this
study was to determine whether topical rebamipide effectively reduced the severity
of oral mucositis induced by chemoradiotherapy.</p></sec><sec sec-type="materials|methods"><title>MATERIAL AND METHODS</title><p><bold>Study design and patient eligibility</bold></p><p>The study design and informed consent disclosure were approved by the Institutional
Ethics Committee of Tokyo Medical University and in accordance with the percepts
established by the Helsinki Declaration. Patients declared their willingness to
participate in the study once the details of the study and the treatment involved
had been explained to them. </p><p>The subjects were patients with cancer of the oral cavity who visited the Department
of Oral and Maxillofacial Surgery (Tokyo Medical University Hospital), and were
scheduled to receive chemoradiotherapy between January 2005 and May 2008. All
patients in this study were older than 20 years of age, had normal renal and liver
functions, and were required to have a Karnofsky performance status ranging between
90 and 100%. Both primary radical chemoradiotherapy and preoperative
chemoradiotherapy patients were eligible for enrolment. In addition, patients with
recurrence of cancer of the oral cavity were eligible. Exclusion criteria included
insulin-dependent diabetes, use of non-steroidal anti-inflammatory drugs or aspirin,
use of dentures, and allergy to rebamipide. All patients enrolled in the study gave
their written informed consent. All patients had the right to withdraw from the
study at any time. In this prospective, double-blind, placebo-controlled study,
patients were assigned to the groups by computer-based 1:1 ratio randomization to
receive either rebamipide gargle or placebo solution. A total of 24 patients met the
inclusion and exclusion criteria. All patients were treated with 2 Gy/fraction for
at least 4 weeks using conventional radiation techniques as both primary radical and
preoperative therapy. Chemotherapy was scheduled as weekly 10 mg/m<sup>2</sup> docetaxel
infusion for 4 weeks (Days 1, 8, 15, and 22). Standard oral and dental care was
provided to all patients during the study. </p><p><bold>Gargle solutions and gargling methods</bold></p><p>The gargle solution was prepared by the method of Hanawa et al. [<xref ref-type="bibr" rid="B14">14</xref>]. A one-day volume (300 mL) of rebamipide
gargle solution contained 300 mg of rebamipide, as well as 3.0 g of Alcox E-30<sup>&#x000ae;</sup>
resin (Meisei Chemical Co., Kyoto, Japan ), which is a polymerized ethylene oxide
(M.W. 300,000 - 500,000), and 1.2 g of Inagel F-13<sup>&#x000ae;</sup> (Ina Food Industry Co., Ltd.
Nagano, Japan), which is a mixture of agar, carageenan, and xanthan gum, to enhance
the viscosity and dispersion of solutions, with the addition of methyl
parahydroxybenzoate (Koso Chemical Co., Ltd., Tokyo, Japan) and propyl
parahydroxybenzoate 0.04 g (reagent supplied by Koso Chemical Co., Ltd., Tokyo) as
preservatives (<xref ref-type="table" rid="T1">Table 1</xref>
). In addition, 6 mL of
4% lidocaine was added to the gargle solutions. The placebo gargle solution
contained all ingredients except for rebamipide. The gargle solution, at 300 mL per
bottle for one day, was used in 6 divided doses, i.e., 50 mL after every meal, as
well as at 10 a.m., 3 p.m., and before going to bed. Subjects were instructed to
gargle for 2 - 3 minutes each time, and not to rinse out the gargle with water for 10
minutes after each gargle. This gargle solution can be stored for a maximum of 3
weeks, according to the results of the investigation performed by the Department of
Pharmacy of the hospital (data not shown). Because of the bitterness of lidocaine
and rebamipide, pineapple flavor was added and dissolved immediately before use of
both types of gargle solutions. All subjects received an information sheet
describing how to use the gargle solution, and were given a full explanation before
starting the study. Gargling was started at the initiation of radiotherapy and was
continued until final irradiation.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Rebamipide Gargle solution for 1-day volume</p></caption><table frame="hsides" rules="groups" width="500"><tbody><tr><td rowspan="1" colspan="1"> Rebamipide </td><td rowspan="1" colspan="1"> 0.3 g </td></tr><tr><td rowspan="1" colspan="1"> Alkox E-30<sup>&#x000ae;</sup> (polymerised ethylene oxide) </td><td rowspan="1" colspan="1"> 3.0 g </td></tr><tr><td rowspan="1" colspan="1"> Inagel F-13<sup>&#x000ae;</sup> (mixture of agar, xanthan gum, and
carageenan) </td><td rowspan="1" colspan="1"> 1.2 g </td></tr><tr><td rowspan="1" colspan="1"> Methyl parahydroxybenzoate </td><td rowspan="1" colspan="1"> 0.08 g </td></tr><tr><td rowspan="1" colspan="1"> Propyl parahydroxybenzoate </td><td rowspan="1" colspan="1"> 0.04 g </td></tr><tr><td rowspan="1" colspan="1"> 4% Lidocaine hydrochloride </td><td rowspan="1" colspan="1"> 6 ml </td></tr><tr><td rowspan="1" colspan="1"> Distilled water </td><td rowspan="1" colspan="1"> Total 300 mL </td></tr></tbody></table></table-wrap><p><bold>Study endpoints and statistics</bold></p><p>After the initiation of gargling, the same study physician, who was blinded to the
solution used by each patient, evaluated them every other week. Grading of oral
mucositis was performed using the WHO oral toxicity scale [<xref ref-type="bibr" rid="B16">16</xref>] of 0 - 4 (0: normal, no mucositis; 1: soreness and
erythema; 2: erythema, ulcers, can eat solids; 3: ulcers, requires liquid diet only;
4: alimentation not possible). The primary endpoint of the study was the incidence
of severe mucositis (WHO grade 3 or 4) after 4 weeks on chemoradiotherapy because in
our previous study [<xref ref-type="bibr" rid="B16">16</xref>] we found the peak
frequency of oral mucositis (&#x02265; WHO Grade 3) at this time point. Patients who
were used drip-feed therapy included Grade 4. Tumour response to chemoradiotherapy
was assessed by the Response Evaluation Criteria in Solid Tumours (RECIST) [<xref ref-type="bibr" rid="B18">18</xref>], 4 weeks after the end of
chemoradiotherapy. The effective response rate (complete response + partial
response) in each group was also evaluated. When data were not available, we used
the last-observation-carried-forward strategy for intention-to-treat analysis
(LOCF-ITT).</p><p><bold>Statistical analysis</bold></p><p> Differences between the two groups were evaluated by Mann-Whitney test for
continuous variables, Fisher's exact test and Monte Carlo test for categorical
variables. &#x003c7;2 = Chi-Square test was applied for nonparametric variables. The P
values cited are two-sided, and when less than 0.05 were considered significant.</p></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 24 patients were enrolled in this study. Of these, 12 were in the
rebamipide gargle arm and 12 in the placebo arm. Their characteristics before
treatment are shown in <xref ref-type="table" rid="T2">Table 2</xref>. They
consisted of 14 men and 10 women, whose age ranged from 32 to 82 years (mean = 60
years). The mean age of the rebamipide group was lower than that of the placebo
group, but there was no significant differences (P = 0.077). Although the rebamipide
group had more Stage I and II patients and the placebo group more stage IV patients,
there were no significant differences between the two arms either in stage or other
parameters. In addition, there were no differences between the two arms in T size
and leukocyte or neutrophil count</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Patient background</p></caption><table frame="hsides" rules="groups" width="630"><thead><tr><td colspan="2" rowspan="1">
</td><td align="center" rowspan="1" colspan="1">
<bold>Placebo gargle</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Rebamipide gargle</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>P</bold>
</td></tr></thead><tbody><tr><td colspan="2" rowspan="1">
<bold>Sex (Male/Female)</bold>
</td><td align="center" rowspan="1" colspan="1"> 7/5 </td><td align="center" rowspan="1" colspan="1"> 7/5 </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td rowspan="6" align="center" colspan="1">
<bold>Age (years)</bold>
</td><td align="center" rowspan="1" colspan="1"> 31-40 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 2 </td><td rowspan="6" align="center" colspan="1"> &#x003c7;<sup>2</sup> = 6.8;<break/>
df = 5;<break/>
P = 0.238<sup>b</sup>
</td></tr><tr><td align="center" rowspan="1" colspan="1"> 41-50 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 2 </td></tr><tr><td align="center" rowspan="1" colspan="1"> 51-60 </td><td align="center" rowspan="1" colspan="1"> 5 </td><td align="center" rowspan="1" colspan="1"> 5 </td></tr><tr><td align="center" rowspan="1" colspan="1"> 61-70 </td><td align="center" rowspan="1" colspan="1"> 2 </td><td align="center" rowspan="1" colspan="1"> 2 </td></tr><tr><td align="center" rowspan="1" colspan="1"> 71-80 </td><td align="center" rowspan="1" colspan="1"> 4 </td><td align="center" rowspan="1" colspan="1"> 1 </td></tr><tr><td align="center" rowspan="1" colspan="1"> 81-90 </td><td align="center" rowspan="1" colspan="1"> 1 </td><td align="center" rowspan="1" colspan="1"> 0 </td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td colspan="2" rowspan="1">
<bold>Mean age (SD)</bold>
</td><td align="center" rowspan="1" colspan="1"> 65.9 (10.8) </td><td align="center" rowspan="1" colspan="1"> 54.9 (11.5) </td><td align="center" rowspan="1" colspan="1"> 0.077<sup>b</sup>
</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td colspan="2" rowspan="1">
<bold>Primary site of cancer</bold>
</td><td colspan="3" align="center" rowspan="1"/></tr><tr><td colspan="2" rowspan="1"> Maxillary gingiva </td><td align="center" rowspan="1" colspan="1"> 3 </td><td align="center" rowspan="1" colspan="1"> 2 </td><td rowspan="5" align="center" colspan="1"> &#x003c7;<sup>2</sup> = 3.7;<break/>
df = 4;<break/>
P = 0.522<sup>b</sup>
</td></tr><tr><td colspan="2" rowspan="1"> Mandibular gingiva </td><td align="center" rowspan="1" colspan="1"> 4 </td><td align="center" rowspan="1" colspan="1"> 3 </td></tr><tr><td colspan="2" rowspan="1"> Tongue </td><td align="center" rowspan="1" colspan="1"> 2 </td><td align="center" rowspan="1" colspan="1"> 6 </td></tr><tr><td colspan="2" rowspan="1"> Oral floor </td><td align="center" rowspan="1" colspan="1"> 2 </td><td align="center" rowspan="1" colspan="1"> 1 </td></tr><tr><td colspan="2" rowspan="1"> Buccal mucosa </td><td align="center" rowspan="1" colspan="1"> 1 </td><td align="center" rowspan="1" colspan="1"> 0 </td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td colspan="2" rowspan="1">
<bold>Initial/relapse</bold>
</td><td align="center" rowspan="1" colspan="1"> 11/1 </td><td align="center" rowspan="1" colspan="1"> 11/1 </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td colspan="2" rowspan="1">
<bold>Stage of cancer</bold>
</td><td colspan="3" align="center" rowspan="1"/></tr><tr><td colspan="2" rowspan="1"> Stage I </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 4 </td><td rowspan="4" align="center" colspan="1"> &#x003c7;<sup>2 </sup>= 6.0;<break/>
df = 3;<break/>
P = 0.125<sup>b</sup>
</td></tr><tr><td colspan="2" rowspan="1"> Stage II </td><td align="center" rowspan="1" colspan="1"> 4 </td><td align="center" rowspan="1" colspan="1"> 4 </td></tr><tr><td colspan="2" rowspan="1"> Stage III </td><td align="center" rowspan="1" colspan="1"> 1 </td><td align="center" rowspan="1" colspan="1"> 1 </td></tr><tr><td colspan="2" rowspan="1"> Stage IV </td><td align="center" rowspan="1" colspan="1"> 6 </td><td align="center" rowspan="1" colspan="1"> 2 </td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td colspan="2" rowspan="1">
<bold>T size of cancer</bold>
</td><td colspan="3" align="center" rowspan="1"/></tr><tr><td colspan="2" rowspan="1"> T<sub>1</sub>
</td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 4 </td><td rowspan="4" align="center" colspan="1"> &#x003c7;<sup>2</sup> = 7.2;<break/>
df = 3;<break/>
P = 0.065<sup>b</sup>
</td></tr><tr><td colspan="2" rowspan="1"> T<sub>2</sub>
</td><td align="center" rowspan="1" colspan="1"> 5 </td><td align="center" rowspan="1" colspan="1"> 5 </td></tr><tr><td colspan="2" rowspan="1"> T<sub>3</sub>
</td><td align="center" rowspan="1" colspan="1"> 3 </td><td align="center" rowspan="1" colspan="1"> 2 </td></tr><tr><td colspan="2" rowspan="1"> T<sub>4</sub>
</td><td align="center" rowspan="1" colspan="1"> 3 </td><td align="center" rowspan="1" colspan="1"> 0 </td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td colspan="2" rowspan="1">
<bold>WBC<sup>a</sup> count at baseline, mean (SD)</bold>
</td><td align="center" rowspan="1" colspan="1"> 6.56 (1.83) </td><td align="center" rowspan="1" colspan="1"> 5.80 (2.15) </td><td align="center" rowspan="1" colspan="1"> 0.34<sup>b</sup>
</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td colspan="2" rowspan="1">
<bold>Neutrophil<sup>a</sup> count at baseline, mean (SD)</bold>
</td><td align="center" rowspan="1" colspan="1"> 3.94 (1.37) </td><td align="center" rowspan="1" colspan="1"> 3.61 (2.15) </td><td align="center" rowspan="1" colspan="1"> 0.48<sup>b</sup>
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup>&#x000d7;10<sup>3</sup> cells/mm<sup>3</sup>.</p><p><sup>b</sup>No statistically significant at the level P &#x0003c; 0.05 (Monte Carlo test).</p><p>SD = Standard deviation; WBC = White Blood Cell; &#x003c7;<sup>2</sup> = Chi-Square.</p></fn></table-wrap-foot></table-wrap><p>Patients in both arms reported good treatment compliance, with no complaints
regarding taste. Two patients in the placebo group dropped out after 30 Gy radiation
because they were unable to continue gargling due to severe (grades 3 and 4) oral
mucositis. Chemoradiotherapy was continued for the two patients who dropped out. On
the basis of LOCF criteria, the WHO score of two dropped out patients at the end of
30 Gy were adopted at the end of score of 40 Gy. No patient developed grade &#x02265;
3 oral mucositis in the rebamipide group by the end of 30 Gy radiation, compared to
4 patients (33.3%) in the placebo group (not significant: P = 0.11). All patients in
both groups developed grade &#x02265; 2 oral mucositis by the end of 40 Gy radiation
therapy (primary endpoint), as shown in <xref ref-type="table" rid="T3">Table
3</xref>. As for the incidence of Grade 3 - 4 oral mucositis, 83% of the
patients in the placebo group developed grade &#x02265; 3 oral mucositis, compared to
33.3% in the rebamipide group (P = 0.036) (<xref ref-type="fig" rid="fig2">Figure
2</xref> and <xref ref-type="table" rid="T3">Table 3</xref>). In addition, the
tumour response to chemoradiotherapy was not affected by rebamipide gargle, as shown
in <xref ref-type="table" rid="T4">Table 4</xref>. There were no patients who were
used gastric fistula. No adverse effects related to the drug or the infusions were
noted in either group.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Incidence of oral mucositis after radiotherapy for oral cancer</p></caption><table frame="hsides" rules="groups" width="595"><thead><tr><td rowspan="2" align="center" colspan="1">
<bold>Incidence of oral mucositis</bold><break/>
<bold>(WHO) grade </bold></td><td colspan="3" align="center" rowspan="1">
<bold>Placebo gargle</bold><break/>
<bold>(n = 12)</bold>
</td><td align="center" rowspan="1" colspan="1"/><td colspan="3" align="center" rowspan="1">
<bold>Rebamipide gargle</bold><break/>
<bold>(n = 12)</bold>
</td><td rowspan="2" align="center" colspan="1">
<bold>P<sup>a</sup></bold><break/>
<bold>(after 40 Gy)</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
<bold>20 Gy</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>30 Gy</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>40 Gy</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>20 Gy</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>30 Gy</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>40 Gy</bold>
</td></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"> Grade 0 </td><td align="center" rowspan="1" colspan="1"> 4 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"> 8 </td><td align="center" rowspan="1" colspan="1"> 1 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"> Grade 1 </td><td align="center" rowspan="1" colspan="1"> 4 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"> 2 </td><td align="center" rowspan="1" colspan="1"> 2 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"> Grade 2 </td><td align="center" rowspan="1" colspan="1"> 4 </td><td align="center" rowspan="1" colspan="1"> 8 </td><td align="center" rowspan="1" colspan="1"> 2 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"> 2 </td><td align="center" rowspan="1" colspan="1"> 9 </td><td align="center" rowspan="1" colspan="1"> 8 </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"> Grade 3 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 3 </td><td align="center" rowspan="1" colspan="1"> 7 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 3 </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"> Grade 4 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 1 </td><td align="center" rowspan="1" colspan="1"> 3 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 1 </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"> % Grade 3 or 4 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 33.3 </td><td align="center" rowspan="1" colspan="1"> 83.3 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 33.3 </td><td align="center" rowspan="1" colspan="1"> 0.036<sup>a</sup>
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup>Significant at the level P &#x0003c; 0.05 (Fisher's exact test).</p><p>WHO = World Health Organization.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Effect of rebamipide on the response rate to chemoradiotherapy in oral
cancer patients</p></caption><table frame="hsides" rules="groups" width="560"><thead><tr><td rowspan="2" align="center" colspan="1">
<bold>Response rate</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Placebo gargle</bold><break/>
<bold>(n = 12)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Rebamipide gargle</bold><break/>
<bold>(n = 12)</bold>
</td><td rowspan="2" align="center" colspan="1">
<bold>P</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
<bold>N (%)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>N (%)</bold>
</td></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"> Complete response </td><td align="center" rowspan="1" colspan="1"> 1 (8.3) </td><td align="center" rowspan="1" colspan="1"> 2 (16.7) </td><td align="center" rowspan="1" colspan="1"> &#x003c7;<sup>2</sup>=1.5; df=2; P = 0.594<sup>a</sup>
</td></tr><tr><td align="center" rowspan="1" colspan="1"> Partial response </td><td align="center" rowspan="1" colspan="1"> 11 (91.7) </td><td align="center" rowspan="1" colspan="1"> 9 (75) </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"> Stable disease </td><td align="center" rowspan="1" colspan="1"> 0 </td><td align="center" rowspan="1" colspan="1"> 1 (8.3) </td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup>No statistically significant at the level P &#x0003c; 0.05 (Monte Carlo exact test).</p><p>&#x003c7;<sup>2</sup> = Chi-Square.</p></fn></table-wrap-foot></table-wrap><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Schedule of chemoradiotherapy and oral treatment.</p></caption><graphic xlink:href="jomr-02-e3-g001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Incidence and severity of oral mucositis after chemotherapy plus 40 Gy
radiotherapy.</p></caption><graphic xlink:href="jomr-02-e3-g002"/></fig></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Over the past 20 years, while supportive care for adverse effects of cancer treatment
such as nausea, vomiting, and myelosuppression has markedly improved, prevention and
treatment of oral mucositis have been only minimally improved. A comprehensive
understanding of the pathogenesis of oral mucositis induced by chemotherapy,
radiotherapy and chemoradiotherapy, together with a clear definition of risk factors
for development and severity of the lesion, remain under investigation. Multiple
risk factors have been reported for the development of oral mucositis, which Eilers
and Million [<xref ref-type="bibr" rid="B19">19</xref>] classified into two
categories: therapy-related factors, and patient-related factors. In their
classification, therapy-related risk factors are subdivided into five categories: 1)
specific chemotherapy/biotherapy agents, 2) doses of agents and administration
schedule, 3) type of transplant, 4) radiation site and fractionation of radiation,
and 5) combined-modality therapy. In particular, use of chemotherapy with new
anticancer drugs combined with radiotherapy is expected to be effective to treat
head and neck cancer. Chemoradiotherapy is intended to exert synergistic cytotoxic
effects on cancer cells, but it injures normal cells as well. Vera-Llonch et al.
[<xref ref-type="bibr" rid="B3">3</xref>] reported that cumulative radiation of
&#x0003e; 50 Gy was a risk factor for oral mucositis in head and neck cancer. In the
present study, chemotherapy was performed with docetaxel, which has been described
as highly effective for head and neck cancer [<xref ref-type="bibr" rid="B20">20</xref>], and oral mucositis occurred in the placebo group after delivery of
radiation to 20 Gy, with onset of Grade 1 - 2 oral mucositis in 8 (66.7%) of 12
patients. It thus appeared that oral mucositis was enhanced by the combined use of
radiotherapy and docetaxel. Furthermore, it was reported that the incidence of
severe oral mucositis was 13% after docetaxel monotherapy, compared to 98% after
combined treatment with radiation, indicating a striking increase in the incidence
of oral mucositis after combined treatment [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>In the present study as well, the incidence of severe oral mucositis at completion of
delivery of radiation to 40 Gy, the primary endpoint of this study, was 83% in the
placebo group, indicating that combined use of radiotherapy and docetaxel is a
significant risk factor for the development of severe oral mucositis. The dose of
anti-tumour drugs or radiation therapy was not decreased in any patient during this
study; however, Kodaira et al. [<xref ref-type="bibr" rid="B21">21</xref>] reported
dose-limiting toxicity with the same regimen in patients with head and neck cancer. </p><p>On the other hand, patient-related factors include: 1) age, 2) gender, 3) oral health
and hygiene, 4) secretory function of salivary glands, 5) genetic factors, 6) body
mass index, 7) renal function, 8) smoking, and 9) previous cancer treatment. In the
present study, the randomisation performed at the start of the study did not involve
stratification based on age, as a result of which the rebamipide group consisted of
slightly younger patients (<xref ref-type="table" rid="T2">Table 2</xref>). There
have been reports of a higher incidence of severe oral mucositis in patients of
advanced age among those receiving 5-FU [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. But in case of
chemoradiotherapy of head and neck cancer, high incidences of severe oral mucositis
have been reported in younger patients by both Vera-Llonch et al. [<xref ref-type="bibr" rid="B3">3</xref>] and van den Broek et al. [<xref ref-type="bibr" rid="B23">23</xref>]. Although the relationship between age and
risk for oral mucositis remains unclear, it appears that younger patients with head
and neck cancer are indeed at a higher risk for oral mucositis. In the present
study, use of rebamipide reduced the incidence of oral mucositis by half at
completion of radiation to 20 Gy compared with placebo, and significantly reduced
the incidence of severe oral mucositis at completion of radiation to 40 Gy (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="table" rid="T3">Table 3</xref>), indicating a prophylactic effect of rebamipide. Palifermin,
N-truncated recombinant human keratinocyte growth factor-1, is the first drug to be
approved in the world for intervention in patients with oral mucositis following an
aggressive conditioning regimen requiring haematopoietic stem-cell transplantation
for haematologic cancer [<xref ref-type="bibr" rid="B24">24</xref>]. In Japan,
because palifermin has not been launched, various conventional and empiric
ameliorative treatments are used in addition to basic oral care and cryotherapy,
including the following drugs and supplements: vitamins (A, C, and E), sodium
alginate, glutathione, azulene, glutamine, sucralfate, prostaglandins, Chinese
herbal drugs, allopurinol, and cryotherapy with fibrinolysin/deoxyribonuclease ice
balls. Although there are no widely accepted clinical data regarding effective
prevention or treatment of oral mucositis, allopurinol gargle is widely used for
preventing oral mucositis in Japan. Allopurinol is believed to protect cells from
reactive oxygen species (ROS), since it can suppress the production of superoxide
(O2-) by inhibiting xanthine oxidase. Rebamipide also inhibits ROS, via two
mechanisms: inhibiting superoxide production [<xref ref-type="bibr" rid="B11">11</xref>], and scavenging hydroxyl radicals [<xref ref-type="bibr" rid="B12">12</xref>]. Superoxide itself is a relatively weak cytotoxic radical, but is
also a precursor of peroxynitrite and hydroxyl radicals, which are highly toxic.
Thus, in terms of induction of scavenging of ROS, which play an important role in
the initiation of oral mucositis, rebamipide is considered more useful than
allopurinol. In addition, while activation of inflammatory responses and associated
production of cytotoxic inflammatory cytokines are considered important in the cycle
of exacerbation of oral mucositis, rebamipide is known to inhibit IL-8 production by
inhibiting its transcription factor NF&#x003ba;-B, an important trigger of this
condition [<xref ref-type="bibr" rid="B13">13</xref>]. The efficacy of rebamipide
demonstrated in the present study may be the result of suppression of the following
three stages of the onset of oral mucositis suggested by Sonis et al. [<xref ref-type="bibr" rid="B6">6</xref>]: 1) the initiation stage, 2) up-regulation
and generation of messenger signals, and 3) signalling and amplification.</p><p> On the other hand, there has been concern that the effects of rebamipide on COX-2
[<xref ref-type="bibr" rid="B7">7</xref>], PGE2 [<xref ref-type="bibr" rid="B8">8</xref>], and EGF [<xref ref-type="bibr" rid="B9">9</xref>] might influence
cancer cell growth. However, since rebamipide did not influence tumour response to
chemoradiotherapy, it did not appear to influence its therapeutic efficacy. Kawai et
al. [<xref ref-type="bibr" rid="B25">25</xref>] reported that oral administration of
rebamipide did not influence the antitumour effect of fluorouracil drugs in the
Yoshida Sarcoma-bearing rat. Furthermore, Haagen et al. [<xref ref-type="bibr" rid="B26">26</xref>] recently reported that administration of infliximab
(TNF-&#x003b1; antibody) and celecoxib (selective COX-2 inhibitor) did not affect the
onset and aggravation of radiation-induced oral ulcers. It thus appears that these
inflammatory pathways are not involved in the onset and development of oral
mucositis.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>The findings of this randomised study suggest that rebamipide gargle solution may be
an effective means to reduce the severity of chemoradiation-induced oral mucositis
in oral cancer patients. Although it remains unclear which of the various mechanisms
of action of rebamipide contributed to the efficacy of this drug in the present
study, rebamipide appears to be a drug with a unique profile in relation to the
pathophysiology of oral mucositis induced by chemotherapy or radiotherapy. A further
clinical trial in a large number of patients is needed to confirm our findings.</p></sec></body><back><ack><sec sec-type="acknowledgments and disclosure statements"><title>ACKNOWLEDGMENTS AND DISCLOSURE STATEMENTS</title><p>The authors declare that they have no conflict of interests.</p></sec></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Kolokythas</surname><given-names>A</given-names></name></person-group><source>Long-term surgical complications in the oral cancer patient: A
comprehensive review. Part II. J Oral Maxillofac Res. 2010 July-Sep;1(3):e2.</source><comment>URL: <ext-link ext-link-type="uri" xlink:href="http://www.ejomr.org/JOMR/archives/2010/3/e2/e2ht.htm">http://www.ejomr.org/JOMR/archives/2010/3/e2/e2ht.htm</ext-link>.</comment><pub-id pub-id-type="doi">10.5037/jomr.2010.1302</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>DE</given-names></name></person-group><source>New strategies for management of oral mucositis in cancer patients. J
Support Oncol. 2006 Feb;4 (2 Suppl 1):9-13.</source><pub-id pub-id-type="pmid">16499139</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Vera-Llonch</surname><given-names>M</given-names></name><name><surname>Oster</surname><given-names>G</given-names></name><name><surname>Hagiwara</surname><given-names>M</given-names></name><name><surname>Sonis</surname><given-names>S</given-names></name></person-group><source>Oral mucositis in patients undergoing radiation treatment for head and
neck carcinoma. Cancer. 2006 Jan 15;106(2):329-36.</source><pub-id pub-id-type="doi">10.1002/cncr.21622</pub-id><pub-id pub-id-type="pmid">16342066</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Sonis</surname><given-names>ST</given-names></name></person-group><source>Pathobiology of oral mucositis: novel insights and opportunities. J
Support Oncol. 2007 Oct;5 (9 Suppl 4):3-11.</source><pub-id pub-id-type="pmid">18046993</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>GM</given-names></name><name><surname>Awde</surname><given-names>JD</given-names></name><name><surname>Ghandi</surname><given-names>H</given-names></name><name><surname>Vincent</surname><given-names>M</given-names></name><name><surname>Kocha</surname><given-names>WI</given-names></name></person-group><source>Risk factors associated with mucositis in cancer patients receiving
5-fluorouracil. Oral Oncol. 1998 Nov;34(6):484-90.</source><pub-id pub-id-type="pmid">9930359</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Sonis</surname><given-names>ST</given-names></name><name><surname>Elting</surname><given-names>LS</given-names></name><name><surname>Keefe</surname><given-names>D</given-names></name><name><surname>Peterson</surname><given-names>DE</given-names></name><name><surname>Schubert</surname><given-names>M</given-names></name><name><surname>Hauer-Jensen</surname><given-names>M</given-names></name><name><surname>Bekele</surname><given-names>BN</given-names></name><name><surname>Raber-Durlacher</surname><given-names>J</given-names></name><name><surname>Donnelly</surname><given-names>JP</given-names></name><name><surname>Rubenstein</surname><given-names>EB</given-names></name></person-group><source>Mucositis Study Section of the Multinational Association for Supportive
Care in Cancer;International Society for Oral Oncology. Perspectives on
cancer therapy-induced mucosal injury: pathogenesis, measurement,
epidemiology, and consequences for patients. Cancer. 2004 May 1;100(9
Suppl):1995-2025.</source><pub-id pub-id-type="doi">10.1002/cncr.20162</pub-id><pub-id pub-id-type="pmid">15108222</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>WH</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Tsujii</surname><given-names>M</given-names></name><name><surname>Gunawan</surname><given-names>ES</given-names></name><name><surname>Kawai</surname><given-names>N</given-names></name><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>Kakiuchi</surname><given-names>Y</given-names></name><name><surname>Yasumaru</surname><given-names>M</given-names></name><name><surname>Iijima</surname><given-names>H</given-names></name><name><surname>Okuda</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Hori</surname><given-names>M</given-names></name><name><surname>Kawano</surname><given-names>S</given-names></name></person-group><source>Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a
mucoprotective agent. J Pharmacol Exp Ther. 2000 Nov;295(2):447-52.</source><pub-id pub-id-type="pmid">11046075</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Tarnawski</surname><given-names>A</given-names></name><name><surname>Arakawa</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name></person-group><source>Rebamipide treatment activates epidermal growth factor and its receptor
expression in normal and ulcerated gastric mucosa in rats: one mechanism for
its ulcer healing action? Dig Dis Sci. 1998 Sep;43(9 Suppl):90S-98S.</source><pub-id pub-id-type="pmid">9753233</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Udagawa</surname><given-names>A</given-names></name><name><surname>Shiota</surname><given-names>G</given-names></name><name><surname>Ichiba</surname><given-names>M</given-names></name><name><surname>Murawaki</surname><given-names>Y</given-names></name></person-group><source>Effect of rebamipide on acetic acid-induced gastric ulcer in rats:
involvement of hepatocyte growth factor. Scand J Gastroenterol. 2003
Feb;38(2):141-6.</source><pub-id pub-id-type="pmid">12678329</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Ishihara</surname><given-names>K</given-names></name><name><surname>Komuro</surname><given-names>Y</given-names></name><name><surname>Nishiyama</surname><given-names>N</given-names></name><name><surname>Yamasaki</surname><given-names>K</given-names></name><name><surname>Hotta</surname><given-names>K</given-names></name></person-group><source>Effect of rebamipide on mucus secretion by endogenous
prostaglandin-independent mechanism in rat gastric mucosa.
Arzneimittelforschung. 1992 Dec;42(12):1462-6.</source><pub-id pub-id-type="pmid">1337697</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>CD</given-names></name><name><surname>Hong</surname><given-names>KW</given-names></name></person-group><source>Preventive effect of rebamipide on gastric lesions induced by
ischemia-reperfusion in the rat. J Pharmacol Exp Ther. 1995 Oct;275(1):
340-4.</source><pub-id pub-id-type="pmid">8387788</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Naito</surname><given-names>Y</given-names></name><name><surname>Tanigawa</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>M</given-names></name></person-group><source>Free radical scavenging activity of the novel anti-ulcer agent
rebamipide studied by electron spin resonance. Arzneimittelforschung. 1993
Mar;43(3):363-6.</source><pub-id pub-id-type="pmid">11454909</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Masamune</surname><given-names>A</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Sakai</surname><given-names>Y</given-names></name><name><surname>Shimosegawa</surname><given-names>T</given-names></name></person-group><source>Rebamipide inhibits ceramide-induced interleukin-8 production in Kato
III human gastric cancer cells. J Pharmacol Exp Ther. 2001
Aug;298(2):485-92.</source><pub-id pub-id-type="pmid">11454909</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Katada</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Isozaki</surname><given-names>Y</given-names></name><name><surname>Tomatsuri</surname><given-names>N</given-names></name><name><surname>Ichikawa</surname><given-names>H</given-names></name><name><surname>Naito</surname><given-names>Y</given-names></name><name><surname>Okanoue</surname><given-names>T</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name></person-group><source>Prevention by rebamipide of acute reflux esophagitis in rats. Dig Dis
Sci. 2005 Oct;50 Suppl 1:S97-S103.</source><pub-id pub-id-type="doi">10.1007/s10620-005-2813-4</pub-id><pub-id pub-id-type="pmid">16184428</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Hanawa</surname><given-names>T</given-names></name><name><surname>Masuda</surname><given-names>N</given-names></name><name><surname>Mohri</surname><given-names>K</given-names></name><name><surname>Kawata</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Nakajima</surname><given-names>S</given-names></name></person-group><source>Development of patient-friendly preparations: preparation of a new
allopurinol mouthwash containing polyethylene(oxide) and carrageenan. Drug
Dev Ind Pharm. 2004 Feb;30(2):151-61.</source><pub-id pub-id-type="pmid">15089049</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>AB</given-names></name><name><surname>Hoogstraten</surname><given-names>B</given-names></name><name><surname>Staquet</surname><given-names>M</given-names></name><name><surname>Winkler</surname><given-names>A</given-names></name></person-group><source>Reporting results of cancer treatment. Cancer. 1981 Jan;47(1):207-14.</source><pub-id pub-id-type="pmid">7459811</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Chiba</surname><given-names>H</given-names></name><name><surname>Satomi</surname><given-names>T</given-names></name><name><surname>Matsuo</surname><given-names>A</given-names></name><name><surname>Kaneko</surname><given-names>T</given-names></name><name><surname>Miyamatsu</surname><given-names>H</given-names></name></person-group><source>[A pilot study of rebamipide-gargle for chemoradiotherapy-induced
mucositis in oral cancer patients] Gan To Kagaku Ryoho. 2008
Jul;35(7):1157-61.</source><pub-id pub-id-type="pmid">18633254</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Mazumdar</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>LH</given-names></name></person-group><source>A statistical simulation study finds discordance between WHO criteria
and RECIST guideline. J Clin Epidemiol. 2004 Apr;57(4):358-65.</source><pub-id pub-id-type="doi">10.1016/j.jclinepi.2003.07.015</pub-id><pub-id pub-id-type="pmid">15135836</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Eilers</surname><given-names>J</given-names></name><name><surname>Million</surname><given-names>R</given-names></name></person-group><source>Prevention and management of oral mucositis in patients with cancer.
Semin Oncol Nurs. 2007 Aug;23(3):201-12.</source><pub-id pub-id-type="doi">10.1016/j.soncn.2007.05.005</pub-id><pub-id pub-id-type="pmid">17693347</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Nabell</surname><given-names>L</given-names></name><name><surname>Spencer</surname><given-names>S</given-names></name></person-group><source>Docetaxel with concurrent radiotherapy in head and neck cancer. Semin
Oncol. 2003 Dec;30(6 Suppl 18):89-93.</source><pub-id pub-id-type="doi">10.1053/j.seminoncol.2003.11.017</pub-id><pub-id pub-id-type="pmid">14727247</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Kodaira</surname><given-names>T</given-names></name><name><surname>Fuwa</surname><given-names>N</given-names></name><name><surname>Furutani</surname><given-names>K</given-names></name><name><surname>Tachibana</surname><given-names>H</given-names></name><name><surname>Yamazaki</surname><given-names>T</given-names></name></person-group><source>Phase I trial of weekly docetaxel and concurrent radiotherapy for head
and neck cancer in elderly patients or patients with complications. Jpn J
Clin Oncol. 2005 Apr;35(4):173-6.</source><pub-id pub-id-type="doi">10.1093/jjco/hyi058</pub-id><pub-id pub-id-type="pmid">15845564</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Zalcberg</surname><given-names>J</given-names></name><name><surname>Kerr</surname><given-names>D</given-names></name><name><surname>Seymour</surname><given-names>L</given-names></name><name><surname>Palmer</surname><given-names>M</given-names></name></person-group><source>Haematological and non-haematological toxicity after 5-fluorouracil and
leucovorin in patients with advanced colorectal cancer is significantly
associated with gender, increasing age and cycle number. Tomudex
International Study Group. Eur J Cancer. 1998 Nov;34(12):1871-5.</source><pub-id pub-id-type="doi">10.1016/S0959-8049(98)00259-7</pub-id><pub-id pub-id-type="pmid">10023308</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>van</surname><given-names>den Broek GB</given-names></name><name><surname>Balm</surname><given-names>AJ</given-names></name><name><surname>van</surname><given-names>den Brekel MW</given-names></name><name><surname>Hauptmann</surname><given-names>M</given-names></name><name><surname>Schornagel</surname><given-names>JH</given-names></name><name><surname>Rasch</surname><given-names>CR</given-names></name></person-group><source>Relationship between clinical factors and the incidence of toxicity
after intra-arterial chemoradiation for head and neck cancer. Radiother
Oncol. 2006 Nov;81(2):143-50.</source><pub-id pub-id-type="doi">10.1016/j.radonc.2006.09.002</pub-id><pub-id pub-id-type="pmid">17055096</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Blijlevens</surname><given-names>N</given-names></name><name><surname>Sonis</surname><given-names>S</given-names></name></person-group><source>Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic
growth factor with multiple biological activities in preventing
chemotherapy- and radiotherapy-induced mucositis. Ann Oncol. 2007
May;18(5):817-26. Epub 2006 Oct 9.</source><pub-id pub-id-type="doi">10.1093/annonc/mdl332</pub-id><pub-id pub-id-type="pmid">17030544</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>K</given-names></name><name><surname>Asakuni</surname><given-names>T</given-names></name><name><surname>Ishiyama</surname><given-names>H</given-names></name><name><surname>Azuma</surname><given-names>A</given-names></name><name><surname>Otsuji</surname><given-names>S</given-names></name><name><surname>Ichikawa</surname><given-names>H</given-names></name><name><surname>Ono</surname><given-names>Y</given-names></name><name><surname>Takizawa</surname><given-names>H</given-names></name><name><surname>Sekiguchi</surname><given-names>K</given-names></name></person-group><source>Rebamipide does not interfere with the antitumor effect of UFT in a
Yoshida Sarcoma Transplant Model. Iyakuhin Kenkyu.
2001;32(2):51-57.</source></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Haagen</surname><given-names>J</given-names></name><name><surname>Krohn</surname><given-names>H</given-names></name><name><surname>R&#x000f6;llig</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Wolfram</surname><given-names>K</given-names></name><name><surname>D&#x000f6;rr</surname><given-names>W</given-names></name></person-group><source>Effect of selective inhibitors of inflammation on oral mucositis:
preclinical studies. Radiother Oncol. 2009 Sep;92(3):472-6. Epub 2009 Jul 1.</source><pub-id pub-id-type="doi">10.1016/j.radonc.2009.06.006</pub-id><pub-id pub-id-type="pmid">19576646</pub-id></element-citation></ref></ref-list></back></article>